Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00405704 · ClinicalTrials.gov registry record · Phase 3
Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)
A Phase 3 study of Urinary Tract Infections and Vesicoureteral Reflux, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 3
- Development phase
- 607
- Enrollment target
- 19
- Study locations
NCT00405704: Completed Phase 3 study of Urinary Tract Infections and Vesicoureteral Reflux, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
NCT00405704 is a Phase 3 study of Urinary Tract Infections and Vesicoureteral Reflux that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 607 participants, above the 440-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (38% higher). The trial reports 19 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00405704, a Phase 3 study of Urinary Tract Infections and Vesicoureteral Reflux, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 607 participants
- Enrollment target
- 19
- Study locations
Study Summary
In this 2-year, multisite, randomized, placebo-controlled trial involving 607 children with vesicoureteral reflux that was diagnosed after a first or second febrile or symptomatic urinary tract infecton, we evaluated the efficacy of Trimethoprim-Sulfamethoxazole (TMP-SMZ) prophylaxis in preventing recurrences (primary outcome). Secondary outcomes were renal scarring, treatment failure (a composite of recurrences and scarring), and antimicrobial resistance.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Trimethoprim-Sulfamethoxazole
Study Locations (19)
Pennsylvania
- Penn State Hershey Medical Center - Hershey
- Children's Hospital of Philadelphia - Philadelphia
- Children's Hospital of Pittsburgh - Pittsburgh
Ohio
- Akron Children's Hospital - Akron
- Cincinnati Children's Hospital - Cincinnati
Alabama
- University of Alabama - Birmingham
Delaware
- Alfred I. duPont Hospital for Children - Wilmington
District of Columbia
- Children's National Medical Center - Washington D.C.
Illinois
- Ann & Robert Lurie Children's Hospital of Chicago - Chicago
Maryland
- Johns Hopkins School of Medicine - Baltimore
Massachusetts
- Children's Hospital of Boston - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 607 participants |
| Start Date | 2007-05 |
| Est. Completion | 2014-05 |
| Phase | Phase 3 |
What the finished NCT00405704 record still lists
NCT00405704 is an interventional study that assigns participants to a tested intervention. The registered 607 participants enrollment target is mid-sized for trials with a published cap, above the 440-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (38% higher).
The record links to 2 conditions, with Urinary Tract Infections appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00405704 lists 19 locations in 16 states (Pennsylvania, Ohio, Alabama).
Frequently Asked Questions
What is clinical trial NCT00405704 about?
NCT00405704 is a clinical study titled "Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)". In this 2-year, multisite, randomized, placebo-controlled trial involving 607 children with vesicoureteral reflux that was diagnosed after a first or second febrile or symptomatic urinary tract infecton, we evaluated the efficacy of Trimethoprim-Sulfamethoxazole (TMP-SMZ) prophylaxis in preventing r...
What is the current status of trial NCT00405704?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 607 participants. The study started on 2007-05. Estimated completion is 2014-05.
What conditions does trial NCT00405704 study?
This clinical trial studies the following conditions: Urinary Tract Infections, Vesicoureteral Reflux.
What interventions are being tested in trial NCT00405704?
The interventions under investigation include: Placebo (DRUG), Trimethoprim-Sulfamethoxazole (DRUG).
Who is sponsoring clinical trial NCT00405704?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00405704 being conducted?
This trial has 19 study locations across Alabama, Delaware, District of Columbia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Tract Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00405704's enrollment target sits among peer trials
607 7th of 34 higher than 28 of 34 other Urinary Tract Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urinary Tract Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women
COMPLETED · Phase 3
-
Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections
COMPLETED · Phase 3
-
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
RECRUITING · Phase 1
-
Application of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting
RECRUITING · NA
-
NextGen - Clinical Implication of Next Generation Sequencing
RECRUITING · Phase 4
-
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02064673 · 608 participants · Phase 3
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
- NCT06091202 · 608 participants · Phase 3
Tele-Collaborative Outreach to Rural Patients With Chronic Pain
- NCT06098144 · 608 participants · Phase 4
Smoking Cessation Program in the Construction Sector
- NCT02342444 · 606 participants · Phase 4
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia